Pharmaceutical Diagnostics

Our pharmaceutical products enhance patient imaging procedures to improve clinical decision making

We are the leading supplier of contrast media and molecular imaging agents for medical imaging examinations. Our products help healthcare professionals in 130 + countries to diagnose, treat and monitor patients across all major disease pathways including neurology, cardiology and oncology. Our customers include Radiology and Nuclear Medicine departments and pharmaceutical companies.

Key facts

4/sec

Four patient procedures per second supported by our products¹

4,000+

employees worldwide

$2.3BN

revenue in 2023²

Our Pharmaceutical Diagnostics Products

 

Contrast Media

Contrast media helps improve the visibility of specific organs, blood vessels or tissues during imaging procedures

 

Molecular Imaging Agents

Used with SPECT and PET cameras, molecular imaging agents visualise and measure biological processes in the body, aiding diagnosis, monitoring and treatment

 

Innovation

We also partner with leading clinical, academic, pharmaceutical and research organisations to innovate and commercialise new imaging agents

Decades of experience delivering imaging agents globally

We have seven GE HealthCare-owned, vertically integrated plants, all current good manufacturing process (cGMP)- accredited, producing active ingredient through to finished product. Over the past decade we have invested almost $400 million to increase manufacturing capacity to address growing global demand.
Download our key locations map

Innovating for the future

We have multiple programmes in pre-clinical and clinical phases across contrast media and molecular imaging with research and development hubs located in:
• Amersham, UK
• Marlborough, US
• Oslo, Norway
• Shanghai, China
• Toulouse, France

We also partner with top academic centres in the US, Europe, and Asia.

Committed to environmental sustainability

We are committed to the efficient use of resources required for producing and delivering our imaging agents whilst minimizing our impact on the environment. We also support customers to optimize contrast media use where possible.

REFERENCES
  1. Data on file, GE HealthCare Pharmaceutical diagnostics - Patients impact, 2023
  2. Data on File, GE HealthCare Pharmaceutical Diagnostics revenue, 2023

JB03837UK